Patient education ‘useless’ when it comes to Eliquis adherence: study

Carly Helfand Good news for partners Bristol-Myers Squibb and Pfizer: In a Phase IV study of their new-age anticoagulant, Eliquis, atrial fibrillation patients posted adherence rates ...

Stem cell researcher cleared of misconduct after U-turn

Nick Paul Taylor A stem cell researcher who was accused by colleagues of making up data has been cleared of scientific misconduct. The decision is a boost for Dr. Paolo Macchiarini, ...

China slaps Pfizer with $500,000 in Viagra penalties for pharmacy tie-up

Emily Wasserman Pfizer has no problem keeping sales for Viagra flying high in China, where brand awareness campaigns and changing attitudes toward sex have given it a sizable hold on ...

Alnylam, Medicines Co. say next-gen PCSK9 drug has blockbuster potential

John Carroll FierceBiotech News

Judge halts lawsuit blaming Purdue, Endo and others for epidemic of drug abuse

Eric Palmer It was attention-grabbing when California sued a handful of drugmakers, accusing them of lying about the safety of their high-powered painkillers and blaming them for an ...

Buzz: Ariad soars on reports that Baxalta has come calling about a buyout

John Carroll Shire has been quiet since making its unwelcomed $ 30 billion bid to acquire Baxalta public earlier this month. But Baxalta evidently isn't waiting for the next step ...

The FDA offers a controversial solution to the biosimilars name game

John Carroll The industry has been wrestling for years now over naming the first wave of biosimilars building on the coast of the American drug industry. A lot of companies that develop ...

Celgene nails down $7.2B takeover of Receptos

Eric Palmer Celgene Thursday reported that it had completed its $ 7.2 billion buyout of Receptos. Celgene agreed to pay $ 232 per share for the San Diego-headquartered company, a ...

UPDATED: Novo to spend $1.2B, hire 700 for its first major drug plant in U.S.

Eric Palmer With a game-changing oral diabetes treatment moving through clinical trials, Novo Nordisk will spend about $ 2 billion on its first API plant in the U.S., ...

UPDATED: Verastem shares crater on Twitter chatter around cancer data

John Carroll Shares of Verastem cratered Wednesday morning as the Twitter crowd passed around an abstract on the company's defactinib (VS-6063), highlighting an extremely poor response ...

Syndax banks an $80M crossover round for PhIII cancer drug

John Carroll Two months after signing up AstraZeneca R&D leader Briggs Morrison as its new CEO, Waltham, MA-based Syndax has raised $ 80 million from a syndicate that includes ...

Allergan recalls eye drugs after patients complain of particles, blurred vision

Carly Helfand Since Allergan and Actavis joined hands to become a new-look Allergan, the company has already had to recall a from the Actavis side. Now, it's recalling one from ...
Page 1 of 612345...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS